New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
08:51 EDTIDRAIdera candidate IMO-8400 likely to be failed drug, says Summer Street
Summer Street predicts Idera Pharmaceuticals' IMO-8400, a small-molecule toll-like receptor antagonist being tested as a treatment for psoriasis, will be a failed drug candidate. The firm says Idera is developing a third-generation product, IMO-9200, which indicates the company has low expectations for IMO-8400.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
08:08 EDTIDRAIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 18, 2015
08:37 EDTIDRAIdera Pharmaceuticals appoints Joanna Horobin as Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use